Loading
A phase 2 trial of Melphalan, Bevacizumab in colorectal cancer, run by Delcath Systems Inc., now recruiting.
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease is a phase 2 interventional study registered as NCT06607458 by Delcath Systems Inc., with 90 participants planned, started 2025-08-05 and due to reach its primary completion in 2026-12. Interventions recorded: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone. Conditions listed: Refractory Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Delcath Systems, Melphalan (including hepatic delivery system).
Shares Delcath Systems, Melphalan (including hepatic delivery system).
Shares Melphalan (including hepatic delivery system), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/